** Shares of cosmetic drugmaker Evolus EOLS.O rise 3.7% to $14.88 in extended trade
** Co reports adjusted income of $6.7 million in Q4, compared with a year-ago loss of $3.7 million
** EOLS sees 2025 rev between $345 million and $355 million, versus Wall Street estimates of $351.3 million — LSEG
** Co says annual net revenue can reach at least $700 million by 2028
** EOLS rose 4.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。